Otto Hemminki - Concepedia

Author

Otto Hemminki

University of Helsinki ORCID

Also Known As

O Hemminki, O. Hemminki, O.J. Hemminki, OSSI HEMMINKI, Ossi Hemminki, Otto Hemminki, Suvi Parviainen

113

Publications

Citations

H-Index

Concepts

All Affiliations

University of Helsinki Helsinki University Hospital German Cancer Research Center Heidelberg University Biocenter Finland

About

Otto Hemminki is an author at University of Helsinki specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	417
2	Public Health	1	1	12
3	Cell Biology	1	1	53
4	Family Medicine	1	1	18
5	Gastroenterology	1	1	12

Otto Hemminki

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients Ilkka Liikanen, Laura Ahtiainen, Mari Hirvinen, Molecular Therapy	2013	161
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 João D. Dias, Otto Hemminki, Ioan Diaconu, Gene Therapy Tumor ImmunologyCancer ImmunosurveillanceHuman Monoclonal AntibodyImmunologyTherapeutic Vaccine	2011	147
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Otto Hemminki, Suvi Parviainen, Juuso Juhila, Oncotarget	2015	85
Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer Otto Hemminki, Iulia Diaconu, Vincenzo Cerullo, Molecular Therapy	2012	85
Oncolytic adenovirus based on serotype 3 Otto Hemminki, Gerd Bauerschmitz, Silvio Hemmi, Cancer Gene Therapy PathologyVirologyMedicineViral GeneticsOncolytic Adenovirus	2010	64
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy Ilkka Liikanen, Anniina Koski, Maiju Merisalo-Soikkeli, OncoImmunology	2015	58
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: <scp>R</scp>esults <i>in vitro</i>, in rodents and in humans Simona Bramante, Johanna K. Kaufmann, Ville Veckman, International Journal of Cancer	2015	56
Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus Ilkka Liikanen, Vladia Monsurrò, Laura Ahtiainen, Molecular Therapy Oncolytic AdenovirusesInterferon Pathways MediatesTumor RecurrenceViral PathogenesisImmunology	2011	53
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans Simona Bramante, Anniina Koski, Anja Kipar, International Journal of Cancer Tumor BiologyCancer ImmunosurveillanceMalignant DiseaseOncogenic AgentMedicine	2013	44
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy Sadia Zafar, Suvi Sorsa, Mikko Siurala, OncoImmunology	2018	37

Page 1